NZ626974A - Nicotine formulation - Google Patents

Nicotine formulation

Info

Publication number
NZ626974A
NZ626974A NZ626974A NZ62697413A NZ626974A NZ 626974 A NZ626974 A NZ 626974A NZ 626974 A NZ626974 A NZ 626974A NZ 62697413 A NZ62697413 A NZ 62697413A NZ 626974 A NZ626974 A NZ 626974A
Authority
NZ
New Zealand
Prior art keywords
solution
film
mean
weight
mol
Prior art date
Application number
NZ626974A
Other languages
English (en)
Inventor
Fredrik Hübinette
Original Assignee
Nicoccino Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicoccino Ab filed Critical Nicoccino Ab
Publication of NZ626974A publication Critical patent/NZ626974A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
NZ626974A 2012-03-27 2013-03-15 Nicotine formulation NZ626974A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261615997P 2012-03-27 2012-03-27
EP12161483 2012-03-27
PCT/EP2013/055456 WO2013143891A1 (en) 2012-03-27 2013-03-15 Nicotine formulation

Publications (1)

Publication Number Publication Date
NZ626974A true NZ626974A (en) 2016-09-30

Family

ID=49258262

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ626974A NZ626974A (en) 2012-03-27 2013-03-15 Nicotine formulation

Country Status (21)

Country Link
US (1) US20150096572A1 (cg-RX-API-DMAC10.html)
EP (1) EP2830589B1 (cg-RX-API-DMAC10.html)
JP (2) JP6412492B2 (cg-RX-API-DMAC10.html)
KR (1) KR102038342B1 (cg-RX-API-DMAC10.html)
CN (1) CN104411297B (cg-RX-API-DMAC10.html)
AU (1) AU2013242200B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014023823B1 (cg-RX-API-DMAC10.html)
CA (1) CA2868445C (cg-RX-API-DMAC10.html)
IN (1) IN2014DN08879A (cg-RX-API-DMAC10.html)
MX (1) MX362918B (cg-RX-API-DMAC10.html)
MY (1) MY183216A (cg-RX-API-DMAC10.html)
NZ (1) NZ626974A (cg-RX-API-DMAC10.html)
PL (1) PL2830589T3 (cg-RX-API-DMAC10.html)
RS (1) RS58677B1 (cg-RX-API-DMAC10.html)
RU (1) RU2625836C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201405958RA (cg-RX-API-DMAC10.html)
SI (1) SI2830589T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201900220T1 (cg-RX-API-DMAC10.html)
UA (1) UA116440C2 (cg-RX-API-DMAC10.html)
WO (1) WO2013143891A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201407677B (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3166563T3 (da) * 2014-07-08 2021-02-15 Fertin Pharma As Oralt administrationssystem omfattende to rum
US11007144B2 (en) 2016-11-15 2021-05-18 Klaria Pharma Holding Ab Pharmaceutical formulation
EP3558267B1 (en) * 2016-12-20 2023-04-26 Fertin Pharma A/S A mucoadhesive oromucosal formulation comprising a nicotine complex
GB201808462D0 (en) * 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201812499D0 (en) * 2018-07-31 2018-09-12 Nicoventures Holdings Ltd Method of making aerosol-forming substrate
WO2020136062A1 (en) * 2018-12-28 2020-07-02 Philip Morris Products S.A. Nicotine formulation comprising metal salt
WO2020141177A1 (en) * 2018-12-31 2020-07-09 Philip Morris Products S.A. Liquid nicotine formulation comprising water-immiscible solvents
GB201912505D0 (en) * 2019-08-30 2019-10-16 Klaria Pharma Holding Ab Pharmaceutical formulation
SE544672C2 (en) * 2020-05-07 2022-10-11 Liw Innovation Ab New compositions for oral or nasal use
WO2024037043A1 (zh) * 2023-04-28 2024-02-22 深圳华宝协同创新技术研究院有限公司 用于口腔粘膜的包含尼古丁的薄膜组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86170A (en) 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
CA2178021C (en) * 1996-04-19 1999-09-28 Theodore H. Stanley Tobacco substitute
SE9900215D0 (sv) 1999-01-26 1999-01-26 Pharmacia & Upjohn Ab New use
JP5089840B2 (ja) * 2001-09-25 2012-12-05 救急薬品工業株式会社 ニコチン含有フィルム製剤
GB0508306D0 (en) * 2005-04-25 2005-06-01 Bioprogress Technology Ltd Nicotine dosage forms
SE530184C2 (sv) * 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
US20080286340A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered nicotine containing products
US20080286341A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered coated nicotine containing products
AU2008311350B2 (en) * 2007-10-11 2014-04-03 Philip Morris Products S.A. Smokeless tobacco product
KR20100095581A (ko) * 2007-12-11 2010-08-31 노파르티스 아게 다-영역 필름
PL2405942T3 (pl) * 2009-03-13 2018-04-30 Excellent Tech Products I Sverige Ab Produkt do podawania doustnego

Also Published As

Publication number Publication date
AU2013242200B2 (en) 2017-03-02
SI2830589T1 (sl) 2019-06-28
BR112014023823A2 (cg-RX-API-DMAC10.html) 2017-06-20
EP2830589A1 (en) 2015-02-04
KR102038342B1 (ko) 2019-10-30
CA2868445A1 (en) 2013-10-03
JP6412492B2 (ja) 2018-10-24
BR112014023823B1 (pt) 2022-04-26
JP2017226686A (ja) 2017-12-28
CA2868445C (en) 2020-01-28
WO2013143891A1 (en) 2013-10-03
IN2014DN08879A (cg-RX-API-DMAC10.html) 2015-05-22
SMT201900220T1 (it) 2019-07-11
SG11201405958RA (en) 2014-10-30
MX2014010760A (es) 2015-03-20
RU2014143003A (ru) 2016-05-20
CN104411297A (zh) 2015-03-11
RU2625836C2 (ru) 2017-07-19
ZA201407677B (en) 2016-05-25
CN104411297B (zh) 2017-10-24
MY183216A (en) 2021-02-18
KR20140140021A (ko) 2014-12-08
HK1205679A1 (en) 2015-12-24
EP2830589B1 (en) 2019-02-13
AU2013242200A1 (en) 2014-10-16
PL2830589T3 (pl) 2019-07-31
JP2015516948A (ja) 2015-06-18
UA116440C2 (uk) 2018-03-26
US20150096572A1 (en) 2015-04-09
MX362918B (es) 2019-02-26
RS58677B1 (sr) 2019-06-28

Similar Documents

Publication Publication Date Title
MX2014010760A (es) Formulacion de nicotina.
SE0502900L (sv) Komposition och metod
UA110194C2 (ru) Композиция для дражирования семян
MX342842B (es) Composiciones que tienen concentraciones incrementadas de carboximetilcelulosa.
MX337891B (es) Papel tisu antimicrobiano y proceos para elaborar el mismo.
MY164618A (en) Wellbore servicing compositions comprising a fluid loss agent and methods of making and using same
RU2009109261A (ru) Загущающая композиция с улучшенным развитием вязкости
MX2019011095A (es) Composicion adhesiva y metodo para preparar la misma.
MX2013002153A (es) Composiciones y metodos para mejorar la compatibilidad de las sales herbicidas solubles en agua.
BR112014017403A8 (pt) distribuidor de produto sólido de dissolução controlada
MX338121B (es) Concentrado de alimento gelificado.
MX2015017854A (es) Composicion que comprende glutamico-n, n-diacetato (glda), agua y enzima.
MX2015016073A (es) Metodo de fabricacion de sales antitranspirantes.
EA201691147A1 (ru) Ионные водные композиции
CN103757984B (zh) 一种防霉抗菌装饰纸及其制备方法
UA117343C2 (uk) Композиції целюлози, способи одержання композицій целюлози і продукти, що містять композиції целюлози
PH12014501981A1 (en) Method for producing enteric alginate microcapsules via ionic gelation containing diclofenac or one of the salts thereof and multiparticled pharmaceutical composition containing them
AU2016220032B2 (en) Stabilizing sorbic acid in beverage syrup
MX2017011293A (es) Bebida a base de te.
PL390296A1 (pl) Sposób wytwarzania nanoproszków krzemionkowych o właściwościach biobójczych, zwłaszcza do kompozytów polimerowych
BR112014018138A8 (pt) Composição de tratamento de superfície, meio de impressão e método para preparar uma composição de tratamento de superfície utilizada na fabricação de papel
TR201905664T4 (tr) Nikotin formülasyonu.
MX2020005890A (es) Formulacion de pelicula que comprende vardenafil, metodo para su preparacion y uso de la misma.
RU2011153245A (ru) Способ формирования защитного покрытия для хранения объектов водных биологических ресурсов с использованием модифицированных защитных покрытий
BR112015013068A2 (pt) composições e métodos de uso

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2018 BY CPA GLOBAL

Effective date: 20170307

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2019 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20180307

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2020 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20190301

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2021 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20200303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2022 BY CAMILLA WELLIN / CPA GLOBAL

Effective date: 20210223

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2023 BY CAMILLA WELLIN / CPA GLOBAL CLARIVATE

Effective date: 20220219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2024 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20230302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2025 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20240216

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2026 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20250223

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2027 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20260217